Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRIW) Research & Development (2023 - 2025)

Biofrontera has reported Research & Development over the past 3 years, most recently at $787000.0 for Q4 2025.

  • Quarterly results put Research & Development at $787000.0 for Q4 2025, up 0.51% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (up 77.89% YoY), and the annual figure for FY2025 was $3.7 million, up 78.03%.
  • Research & Development for Q4 2025 was $787000.0 at Biofrontera, down from $854000.0 in the prior quarter.
  • Over the last five years, Research & Development for BFRIW hit a ceiling of $1.2 million in Q1 2025 and a floor of $11000.0 in Q2 2023.
  • Median Research & Development over the past 3 years was $669000.0 (2024), compared with a mean of $535000.0.
  • Peak annual rise in Research & Development hit 7000.0% in 2025, while the deepest fall reached 0.51% in 2025.
  • Biofrontera's Research & Development stood at $33000.0 in 2023, then skyrocketed by 2272.73% to $783000.0 in 2024, then increased by 0.51% to $787000.0 in 2025.
  • The last three reported values for Research & Development were $787000.0 (Q4 2025), $854000.0 (Q3 2025), and $870000.0 (Q2 2025) per Business Quant data.